Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

MultiCell Technologies Inc (EM) MCET

MultiCell Technologies, Inc., a biopharmaceutical company, develops novel therapeutics and discovery tools for the treatment of neurological disorders, hepatic disease, cancer, and interventional cardiology and peripheral vessel applications. Its product portfolio comprises MCT-125, a Phase II therapeutic candidate for the treatment of primary multiple sclerosis-related fatigue; MCT-465, a preclinical synthetic double-stranded RNA (dsRNA) therapeutic candidate and potent immune enhancer for the treatment of solid tumor cancers; and MCT-485, a discovery stage dsRNA therapeutic candidate with tumor cytolytic properties for the treatment of various cancers. The company also develops Ideal BioStent, a bioabsorbable stent for interventional cardiology and peripheral vessel applications. MultiCell Technologies, Inc. has a license agreement with Corning Incorporated and Pfizer Inc. The company was formerly known as Exten Industries, Inc. and changed its name to MultiCell Technologies, Inc....


EXPM:MCET - Post by User

User Avatar Image
(0)
•••
  • MCETDREAMERX
Post by MCETDREAMERon Jun 29, 2021 10:00pm
119 Views
Post# 33471175

The latest company infringing on MCETs patent to come to the

The latest company infringing on MCETs patent to come to theClonetech, Takara bio new to the market as of 2-26-2021 TAKAERA BIO WEBSITE: What's new Takara Bio USA, Inc. elevates the sensitivity of scRNA-seq in its continuing mission to support the efforts of single-cell researcher Takara Bio USA, Inc. continues to provide researchers improved sensitivity and performance for single-cell analysis with the launch of our recent next-generation sequencing product, SMART-Seq Single Cell Kit. 01/26/2021 takarabio.com News Clontech Laboratories & TET Systems Announce the Broadening of Their License Agreement Clontech Laboratories, Inc., a wholly-owned subsidiary of Takara Bio Inc., and TET Systems, a privately-held German biotech company based in Heidelberg, announced that they have signed an amendment to their existing license agreement. Under the expanded license agreement, Clontech obtains r ... more Article An Immortalized Hepatocyte-Like Cell Line (imHC) Accommodated Complete Viral Lifecycle, Viral Persistence Form, cccDNA and Eventual Spreading of a Clinically-Isolated HBV Khanit Sa-ngiamsuntorn, Piyanoot Thongsri, [...], and Suradej Hongeng Additional article information ncbi.nlm.nih.gov 2.3. Production of HBV from Cultured Cells Cell culture based hepatitis B virus (HBVcc subtype adw2) was prepared from freshly collected supernatants of the HBV stably transfected HepG2 cell line, clone 2.2.15 [22]. HepG2.2.15 cells were maintained in DMEM (Hyclone, GE Healthcare), 10% FBS, 100 U/mL penicillin, 100 g/mL streptomycin. The supernatant was collected at 7 d after adding 380 g/mL G418 and concentrated 100-fold. The collected supernatants were filtered through 0.45 m and viral particles were concentrated by Lenti-X Concentrator (Clonetech, Takara Bio, Mountain View, CA, USA). The mixtures were incubated at 4 C at least 30 min before centrifugation at 1500 g for 45 min at 4 C following the manufacturers instructions. Check out Multicell Technology Inc Patent. Google Patent: patents.google.com
<< Previous
Bullboard Posts
Next >>